Your search history is turned on.
Date: April 17, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - REPLICEL News Release announcing loan agreement.docx NEWSRELEASE RepliCel Announces Secured Loan Agreement VANCOUVER, BC, CANADA April 17, 2024 RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (RepliCel or the Company), a company developing next- generaon technologies in aesthecs...
Date: March 20, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - REPLICEL Material Change Report for News Release announcing MCTO (March 18_ 2024)(21720653.1).doc 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company RepliCel Life Sciences Inc. (RepliCel or the Company) 900 570 Granville Street Vancouver, British Columbia, V6C 3P1 Item 2 Date of Material Change Mar...
Date: March 18, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - 2024-03-18 NR Announcing LOI (Asset Purchase) with CW and IIROC comments.docx NEWSRELEASE 1|P a g e RepliCelannouncesaLetterofIntentfor AssetPurchaseAgreement VANCOUVER, BC, CANADA March 18, 2024 RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (RepliCel or t...
Date: November 28, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - REPLICEL CFO Certification for September 30_ 2023(21191976.1).doc Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, David Kwok, Chief Financial Officer of RepliCel Life Sciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the inter...
Microsoft Word - REPLICEL CEO Certification for September 30_ 2023(21191960.1).doc Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Andrew Schutte, President and Chief Executive Officer of RepliCel Life Sciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (t...
CW20199437.1 REPLICEL LIFE SCIENCES INC. MANAGEMENT DISCUSSION AND ANALYSIS FORM 51-102F1 For the period ended September 30, 2023 Dated as of November 28, 2023 This Managements Discussion and Analysis (MD&A) of RepliCel Life Sciences Inc (referred to as RepliCel, the Company, us or our) provides analysis of ...
MOUNTAIN LAKE RESOURCES INC REPLICEL LIFE SCIENCES INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited) For the six months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) The accompanying notes form an integral part of these...
Date: October 23, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - REPLICEL CFO Certification for June 30_ 2023(20998914.1).doc 20998914.1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, David Kwok, Chief Financial Officer of RepliCel Life Sciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the...
Microsoft Word - REPLICEL CEO Certification for June 30_ 2023(20998845.1).doc 20998845.1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Andrew Schutte, President and Chief Executive Officer of RepliCel Life Sciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim ...
Microsoft Word - REPLICEL MD_A for June 30_ 2023(21026347.1).docx REPLICEL LIFE SCIENCES INC. MANAGEMENT DISCUSSION AND ANALYSIS FORM 51-102F1 For the period ended June 30, 2023 Dated as of October 23, 2023 This Managements Discussion and Analysis (MD&A) of RepliCel Life Sciences Inc (referred to as RepliCel, the Company, us or our) provid...